Monograph

M05BC01 - Dibotermin Alfa

Not porphyrinogenic

Rationale

Dibotermin alfa is not metabolized by CYP. The osteoinductive protein is exclusively locally active. In patients subjected to pre-drilling of the bone marrow canal prior to nailing, the frequency of possibly porphyrogenic infection is increased and may motivate attention. There are no other physiological effects of relevance to acute porphyria.

Chemical description

Osteoinductive protein

Therapeutic characteristics

Dibotermin alfa is indicated for spinal fusion operation L4-S1 and open tibia reposition and marrow nailing via pre-drilled canal. It is administered as an injection in connection with marrow nailing or nailing through a predrilled canal.

Hepatic exposure

Insignificant.

Metabolism and pharmacokinetics

Dibotemin alfa is not recovered in the systemic circulation. Preclinical data suggest that any dibotermin alfa escaping the implant to circulation would be rapidly degraded in the same manner as other endogenous proteins. It is not metabolized by cytochrome P450 enzymes.

Similar drugs

Explore alternative drugs in similar therapeutic classes M05B / M05BC or go back.

References

#	Citation details	PMID
*	Drug reference publications
1.	Sweetman SC, editor. Martindale: The complete drug reference. Dibotermin alfa. Pharmaceutical Press 2009.
*	Government bodies
2.	European Public Assessment Report, InducOs (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu
*	Summary of Product Characteristics
3.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). InducOs.

Citation details

PMID

Drug reference publications

Sweetman SC, editor. Martindale: The complete drug reference. Dibotermin alfa. Pharmaceutical Press 2009.

Government bodies

European Public Assessment Report, InducOs (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). InducOs.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames